Revolution Medicines Inc (NASDAQ: RVMD)’s stock price has increased by 4.37 compared to its previous closing price of 37.96. However, the company has seen a -2.17% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2025-02-27 that Revolution Medicines, Inc. (NASDAQ:RVMD ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Ryan Asay – Senior Vice President-Corporate Affairs Mark Goldsmith – Chairman and Chief Executive Officer Jack Anders – Chief Financial Officer Steve Kelsey – President-Research and Development Wei Lin – Chief Medical Officer Conference Call Participants Eric Joseph – J.P. Morgan Marc Frahm – TD Cowen Michael Schmidt – Guggenheim Ben Burnett – Stifel Laura Prendergast – Raymond James Jay Olson – Oppenheimer Joe Catanzaro – Piper Sandler Poorna Kannan – Needham & Company Alex Bouilloux – Barclays Bank Operator Good day, and thank you for standing by.
Is It Worth Investing in Revolution Medicines Inc (NASDAQ: RVMD) Right Now?
Additionally, the 36-month beta value for RVMD is 1.35. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for RVMD is 161.49M and currently, short sellers hold a 9.24% ratio of that float. The average trading volume of RVMD on March 06, 2025 was 1.40M shares.
RVMD’s Market Performance
RVMD stock saw a decrease of -2.17% in the past week, with a monthly decline of -5.98% and a quarterly a decrease of -31.51%. The volatility ratio for the week is 5.93%, and the volatility levels for the last 30 days are 4.05% for Revolution Medicines Inc (RVMD). The simple moving average for the last 20 days is -3.80% for RVMD stock, with a simple moving average of -11.26% for the last 200 days.
Analysts’ Opinion of RVMD
Many brokerage firms have already submitted their reports for RVMD stocks, with Needham repeating the rating for RVMD by listing it as a “Buy.” The predicted price for RVMD in the upcoming period, according to Needham is $62 based on the research report published on July 16, 2024 of the previous year 2024.
Barclays, on the other hand, stated in their research note that they expect to see RVMD reach a price target of $52. The rating they have provided for RVMD stocks is “Overweight” according to the report published on July 12th, 2024.
Jefferies gave a rating of “Buy” to RVMD, setting the target price at $63 in the report published on July 08th of the previous year.
RVMD Trading at -5.54% from the 50-Day Moving Average
After a stumble in the market that brought RVMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.51% of loss for the given period.
Volatility was left at 4.05%, however, over the last 30 days, the volatility rate increased by 5.93%, as shares sank -6.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.80% lower at present.
During the last 5 trading sessions, RVMD fell by -2.17%, which changed the moving average for the period of 200-days by +0.58% in comparison to the 20-day moving average, which settled at $41.19. In addition, Revolution Medicines Inc saw -9.42% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RVMD starting from Cislini Jeff, who sale 2,406 shares at the price of $40.50 back on Jan 21 ’25. After this action, Cislini Jeff now owns 39,222 shares of Revolution Medicines Inc, valued at $97,443 using the latest closing price.
JEFFREY TODD CISLINI, the Officer of Revolution Medicines Inc, proposed sale 2,406 shares at $40.29 during a trade that took place back on Jan 21 ’25, which means that JEFFREY TODD CISLINI is holding shares at $96,938 based on the most recent closing price.
Stock Fundamentals for RVMD
The total capital return value is set at -0.29. Equity return is now at value -29.33, with -25.58 for asset returns.
Based on Revolution Medicines Inc (RVMD), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -4.1.
Currently, EBITDA for the company is -689.52 million with net debt to EBITDA at 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.20.
Conclusion
In conclusion, Revolution Medicines Inc (RVMD) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
